Australian melanoma researcher Georgina Long leads a phase 3 clinical trial testing a personalised mRNA treatment approach for people with melanoma after surgery. The trial aims to evaluate whether tailoring mRNA therapy to an individual’s tumour biology can improve outcomes in the post-operative setting.
The outlets describe the study as a major development in melanoma care and highlight Australia’s involvement in the research effort. While both sources frame the work as a potential breakthrough that could change treatment decisions after surgery, they do not provide further trial details such as enrollment size, timeline, or expected endpoints in the supplied text. Both publications emphasize the same central point: Long’s leadership role in the phase 3 study and the focus on personalised mRNA therapy for melanoma patients once primary treatment is complete.
